Removing the hype from hypertension
作者： M. J. Shun-Shin , J. P. Howard , D. P. Francis
DOI: 10.1136/BMJ.G1937
关键词:
摘要: Symplicity HTN-3 illustrates the importance of randomisation and blinding for exciting new treatments
researchgate.net 
jamesphoward.com 参考文章(8)
Symplicity HTN-2 Investigators, None, Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial The Lancet. ,vol. 376, pp. 1903- 1909 ,(2010) , 10.1016/S0140-6736(10)62039-9
Markus P. Schlaich, Paul A. Sobotka, Henry Krum, Elisabeth Lambert, Murray D. Esler, Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension The New England Journal of Medicine. ,vol. 361, pp. 932- 934 ,(2009) , 10.1056/NEJMC0904179
Matthew James Shun-Shin, Darrel P. Francis, Why Even More Clinical Research Studies May Be False: Effect of Asymmetrical Handling of Clinically Unexpected Values PLoS ONE. ,vol. 8, pp. e65323- ,(2013) , 10.1371/JOURNAL.PONE.0065323
S. J Day, Statistics Notes: Blinding in clinical trials and other studies BMJ. ,vol. 321, pp. 504- 504 ,(2000) , 10.1136/BMJ.321.7259.504
I. Chalmers, P. Glasziou, F. Godlee, All trials must be registered and the results published BMJ. ,vol. 346, pp. 139- 140 ,(2013) , 10.1136/BMJ.F105
David E. Kandzari, Deepak L. Bhatt, Paul A. Sobotka, William W. O'Neill, Murray Esler, John M. Flack, Barry T. Katzen, Martin B. Leon, Joseph M. Massaro, Manuela Negoita, Suzanne Oparil, Krishna Rocha-Singh, Craig Straley, Raymond R. Townsend, George Bakris, Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial Clinical Cardiology. ,vol. 35, pp. 528- 535 ,(2012) , 10.1002/CLC.22008
James P Howard, Alexandra N Nowbar, Darrel P Francis, Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report Heart. ,vol. 99, pp. 1579- 1587 ,(2013) , 10.1136/HEARTJNL-2013-304238
, Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months Hypertension. ,vol. 57, pp. 911- 917 ,(2011) , 10.1161/HYPERTENSIONAHA.110.163014